A Phase I Trial of a Bcl-2 inhibitor and a MEK inhibitor for patients with relapsed indolent B-NHL
Research Grant
Administered By
Medicine, Hematologic Malignancies and Cellular Therapy
Awarded By
Lymphoma Research Foundation of America
Start Date
January 15, 2014
End Date
May 15, 2016
Administered By
Medicine, Hematologic Malignancies and Cellular Therapy
Awarded By
Lymphoma Research Foundation of America
Start Date
January 15, 2014
End Date
May 15, 2016